CBL0137 is our lead oncology drug candidate that interferes with a novel molecular target. It is a proprietary small molecule suitable for oral and intravenous administration.
The interaction of CBL0137 with FACT (Facilitates Chromatin Transcription) complex results in simultaneous NF-kB suppression, Heat Shock Factor 1 suppression and p53 activation. This modulation of three key cellular pathways causes suppression of cancer cell growth. CBL0137 has been shown in preclinical studies to have a beneficial effect in multiple solid tumor animal models.
Two Phase 1 trials with different administrations of CBL0137 are currently ongoing:
A study evaluating intravenous administration of CBL0137 in patients with metastatic or unresectable advanced solid cancers and lymphomas was initiated in August 2013. For more information on this trial, please refer to Clinicaltrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT01905228?term=CBL0137&rank=1
A study assessing oral administration of CBL0137 in patients with advanced solid tumors that are resistant or refractory to current standard treatment was initiated in the Russian Federation in October 2012.
Our majority-owned subsidiary, Incuron, holds worldwide development and commercialization rights to CBL0137.